Lymphoma

Steven M. Horwitz, MD, discussed the PRIMO dosing strategy to manage adverse effects in lymphoma.

Jennifer Effie Amengual, MD, detailed a clinical trial evaluating the dual epigenetic combination of tazemetostat and belinostat for the treatment of T-cell lymphomas.

Jennifer Effie Amengual, MD, discussed using epigenetic drugs to enhance immune surveillance and other novel lymphoma therapeutic strategies.

Craig H. Moskowitz, MD, discussed the transition toward molecularly defined lymphoma care and the declining role of autologous stem cell transplantation.

Hematologic oncologists discussed long-term survival data from the SEQUOIA and ALPINE trials exploring zanubrutinib in frontline and R/R CLL/SLL.

A data monitoring committee recommended the halt for futility of the phase 3 FLASH2 trial evaluating synthetic hypericin in cutaneous T-cell lymphoma.

A total of 48.0% of patients treated with duvelisib experienced a response, 33.3% of whom experienced a complete response.

Experts discussed a case study involving a patient with multiple myeloma who developed CAR T-cell–related lymphomagenesis in the gastrointestinal tract.

Alex Herrera, MD, analyzed the SWOG S1826 trial, highlighting how nivolumab plus AVD improved survival and reduced AEs in advanced Hodgkin lymphoma.

Early trials exploring the efficacy of PD-1 blockade in Hodgkin lymphoma inspired the SWOG S1826 trial, which evaluated the agent with AVD in this population.

At the MRD assessment on day 45, patients with large B-cell lymphoma treated with cema-cel saw a median decrease of 97.7% in their plasma ctDNA levels.

Combining ctDNA and modern imaging with novel therapeutics may help determine subsets of patients who are eligible to receive reduced treatment courses.

A large community-based chart review demonstrates robust real-world responses with tafasitamab/lenalidomide across a racially diverse US population.

According to Jeff P. Sharman, MD, determining whether a patient requires inpatient or outpatient admission is a critical concern in community practice.

Although numerous bispecific agents are FDA approved for large B-cell lymphoma, many did so based on single-arm studies requiring confirmation studies.

The totality of evidence from the phase 2 ZUMA-2 study formed the basis of the regulatory decision.

The next frontier is not only building constructs that reduce one mechanism of relapse, but understanding why antigen-positive failures still occur.

Clinically relevant variants were detected in 64% of samples, with negative results informing response or ruling out central nervous system lymphomas.

Findings from the phase 3 SWOG 1826/CA209-8UT trial support the regulatory decision for this lymphoma population.

Experts from Columbia University highlight approvals in CLL, bispecific antibodies in multiple myeloma, and actionable biomarkers in DLBCL.

An independent data monitoring committee advised that the risks associated with emergent secondary hematologic malignancies may outweigh the benefits.

Irtiza Sheikh, DO, sought to assess the impact of age and clinical setting on liso-cel efficacy in patients with large B-cell lymphoma.

Peter Martin, MD, focused on the collaborative meeting setting and where the MCL research field is headed.

Kami Maddocks, MD, discusses how the push to define high-risk MCL for clinical trials was a focus at the 2025 MCL workshop.